Skip to main content

Table 2 Multinomial logistic regression analyses

From: Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study

 

visceral fat obesity

premetabolic syndrome

metabolic syndrome

Variable

AOR

95% CI

AOR

95% CI

AOR

95% CI

Gender (male)

7.104

2.990-16.879

6.122

2.955-12.683

3.427

1.835-6.401

Smoking habit, per day

      

   21 or more

0.353

0.093-1.337

1.726

0.750-3.974

2.298

1.074-4.916

   6 to 20

0.882

0.357-2.183

1.103

0.483-2.521

1.537

0.714-3.308

   1 to 5

0.480

0.054-4.286

0.784

0.144-4.266

0.736

0.143-3.799

   none (reference)

1

--

1

--

1

--

Duration of psychiatric treatment, y

1.006

0.974-1.039

0.990

0.962-1.019

1.028

1.003-1.054

Total daily dose (10 mg units)

1.011

1.003-1.019

1.007

0.999-1.015

1.005

0.998-1.012

Antipsychotic polypharmacy

1.580

0.709-3.521

2.348

1.181-4.668

1.269

0.679-2.371

  1. The dependent variable has four categories: normal, visceral fat obesity, pre-metabolic, and metabolic syndrome. The latter three categories are compared with the normal category.
  2. AOR: adjusted odds ratio, CI: confidence interval
  3. Nagelkere's R square = 0.26.